TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22023735
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate and high calorie oral nutritional supplement
Study: 22023735
Drug: Placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication and low calorie oral nutritional supplementation
Study: 23621805
Drug: Individual music
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual music therapy for 6 weeks
Study: 19132197
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/day for 10 days
Study: 19132197
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg on day 11
Study: 17324742
Drug: L-NMMA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (3 mg/kg intravenously)
Study: 15002070
Drug: Pentoxifylline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (10 mg/kg)
Study: 11277274
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg single-dose infusion)
Study: 8083102
Drug: lonidamine +
Normalized name: lonidamine
DrugBank: Lonidamine (DB06266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lonidamine + radiation therapy
Study: 8083102
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + radiation therapy
Study: 2536765
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg fluoxetine
Study: 338109
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg PGE2 in 2% gel
Study: 338109
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg PGE2 in 4% gel
Study: 24887490
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: 20 mg/day lutein and 2 mg/day zeaxanthin
Study: 24887490
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: 10 mg/day meso-zeaxanthin, 10 mg/day lutein, and 2 mg/day zeaxanthin
Study: 24887490
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: 17 mg/day meso-zeaxanthin, 3 mg/day lutein, and 2 mg/day zeaxanthin
Study: 9338554
Drug: Topical fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluticasone propionate
Study: 9338554
Drug: Topical glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glucocorticoid therapy
Study: 29358446
Drug: Fast track
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast track initiation counselling for patients eligible for antiretroviral therapy (ART)
Study: 29358446
Drug: Decentralised medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decentralised medication delivery for stable ART patients
Study: 21076158
Drug: AAD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAD treatment for the first 6 weeks after ablation
Study: 21076158
Drug: No AAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: No AAD treatment for the first 6 weeks after ablation
Study: 18215983
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor dose escalation in response to therapeutic drug monitoring (TDM) with an inhibitory quotient
Study: 14614766
Drug: Leucocyte IFNalpha
Normalized name: Zenalpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucocyte IFNalpha 3MU three times weekly plus ribavirin
Study: 2319467
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg nicotine gum
Study: 11104110
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg nicotine gum
Study: 2319467
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses (2 mg and 4 mg)
Study: 493904
Drug: Cool, dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cool, dry room air (CDA) at 23 degrees C with 3 mg of water and 7.3 cal of heat content/l
Study: 493904
Drug: Over-saturated air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-saturated air (OSA) at room temperature containing 43 mg water and 16.3 cal/l
Study: 493904
Drug: Warm, humidified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm, humidified air (WHA) at 37 degrees C with 43 mg water and 34.7 cal/l
Study: 493904
Drug: Hot, dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hot, dry air (HDA) at 120 degrees C having 3 mg water and 24.4 cal/l
Study: 31478892
Drug: Fentanyl (time-weighted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (time-weighted cumulative dose above the median)
Study: 27926528
Drug: Ketamine (sub-anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (sub-anesthetic dose of racemic ketamine hydrochloride)
Study: 25649801
Drug: High-dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose B vitamin therapy
Study: 25649801
Drug: Low-dose B
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose B vitamin therapy
Study: 23566636
Drug: Low eGFR
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low eGFR (<45 mL/min/1.73 m²)
Study: 21627339
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg) plus Interferon-α (9 MIU)
Study: 21627339
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg) plus Interferon-α (6 MIU)
Study: 21627339
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg) plus Interferon-α (3 MIU)
Study: 21627339
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg)
Study: 18042575
Drug: pegylated-interferon alpha
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegylated-interferon alpha (PEG-2a) monotherapy
Study: 11708311
Drug: Soybean oil-based
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil-based preparation of CoQ10 (300 mg daily for 7 days)
Study: 11708311
Drug: Complex micelle
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex micelle emulsion of CoQ10 (300 mg daily for 7 days)
Study: 11708311
Drug: Both preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both preparations of CoQ10
Study: 9149124
Drug: Carboplatin (CBDCA)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (CBDCA) administered 10 min after achieving target temperature (41.8 degrees C) during the plateau phase of WBH
Study: 9149124
Drug: Carboplatin (CBDCA)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (CBDCA) administered on an early schedule before reaching target temperature
Study: 22954645
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of alcohol
Study: 25282112
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment in PCOS women
Study: 20514951
Drug: Gabapentin 1200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1200 mg preoperatively, then 600 mg twice a day for two days postoperatively
Study: 10799426
Drug: Salbutamol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (200 microg three times daily)
Study: 25898343
Drug: Antidepressant Medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant Medication (ADM)
Study: 10407233
Drug: Treatment exposure
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment exposure (dose)
Study: 7770495
Drug: Multichannel functional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multichannel functional electrical stimulation (MFES) followed by conventional therapy
Study: 7770495
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy followed by multichannel functional electrical stimulation (MFES)
Study: 31402112
Drug: No bowel
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bowel preparation (NBP)
Study: 30058184
Drug: Outpatient multidisciplinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient multidisciplinary therapy (36 weeks)
Study: 24703170
Drug: Adjunctive tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive tamoxifen
Study: 16150764
Drug: Social behaviour
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social behaviour and network therapy
Study: 8621843
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 200 micrograms daily
Study: 25953940
Drug: 3% saline
Normalized name: dextrose 2.5%-0.3% saline (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% saline compresses (Group A) 3 times weekly
Study: 25953940
Drug: Mupirocine 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mupirocine 2% ointment (Group B) 3 times weekly
Study: 25953940
Drug: No aseptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aseptic agents (Group C)
Study: 17178976
Drug: Low-dose quadruple
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose quadruple antihypertensive combination (4 agents at one-quarter dosage; n=22)
Study: 17178976
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg; n=22)
Study: 17178976
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg; n=20)
Study: 17178976
Drug: Bendroflumethiazide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide (2.5 mg; n=22)
Study: 17178976
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg twice daily; n=22)
Study: 17178976
Drug: Low-dose quadruple
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose quadruple antihypertensive combination
Study: 17178976
Drug: Individual drugs
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual drugs (Amlodipine, Atenolol, Bendroflumethiazide, Captopril)
Study: 15595229
Drug: Topical ketoprofen
Normalized name: ketoprofen Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketoprofen 20% in a poloxamer-lecithin organogel (PLO)
Study: 15595229
Drug: Oral 50-mg
Normalized name: hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 50-mg ketoprofen capsule
Study: 10802278
Drug: Nestorone alone
Normalized name: Nestorone
DrugBank: Segesterone acetate (DB14583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nestorone alone (50, 75, 100 µg daily over 6 months)
Study: 10802278
Drug: ethinyl estradiol:
Approvals — FDA: no, EMA: no, PMDA: no
Description: ethinyl estradiol: Nestorone (30:100 and 15:150 µg daily over 6 months)
Study: 10802278
Drug: ethinylestradiol:norethindrone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ethinylestradiol:norethindrone acetate (20:1000 and 15:1000 µg daily over 4 months)
Study: 10802278
Drug: ethinyl estradiol:norethindrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: ethinyl estradiol:norethindrone acetate (20:1000 µg daily over 12 months)
Study: 2062620
Drug: HbOC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbOC vaccine (3-dose regimen, first dose between 6 weeks and 6 months, minimum interval of 1 month between doses, third dose by 1 year of age)
Study: 2062620
Drug: HbOC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbOC vaccine (3-dose regimen)
Study: 2062620
Drug: HbOC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbOC vaccine (1 dose)
Study: 8352217
Drug: HbOC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbOC vaccine
Study: 6339154
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise (standardized exercise programme, 1 hour twice weekly for 8 months)
Study: 22429361
Drug: NUTRIOSE® 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE® 10 g/day for 14 days
Study: 22429361
Drug: NUTRIOSE® 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE® 15 g/day for 14 days
Study: 22429361
Drug: NUTRIOSE® 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE® 20 g/day for 14 days
Study: 22429361
Drug: NUTRIOSE® 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE® 8 g/day for 14 days
Study: 20463176
Drug: Lactate-guided therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate-guided therapy (treatment guided by lactate levels aiming to decrease lactate by 20% or more per 2 hours for the initial 8 hours)
Study: 20463176
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no knowledge of lactate levels during the initial treatment period)
Study: 19301628
Drug: Hand acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand acupuncture treatment
Study: 16306031
Drug: Clarithromycin extended-release
Normalized name: Clarithromycin Extended-Release Tablets
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin extended-release (ER), 1000 mg once daily
Study: 16306031
Drug: Clarithromycin immediate-release
Normalized name: clarithromycin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin immediate-release (IR), 500 mg bid
Study: 12410855
Drug: Lisinopril (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (up to 40 mg/day)
Study: 12410855
Drug: Candesartan (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (up to 32 mg/day)
Study: 12410855
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (lisinopril up to 20 mg/day plus candesartan up to 16 mg/day)
Study: 12410855
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy vs Candesartan alone
Study: 12410855
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy vs Lisinopril only
Study: 10561307
Drug: Eniluracil 10
Normalized name: Eniluracil
DrugBank: Eniluracil (DB03516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eniluracil 10 mg/m(2) twice daily for 3 days before surgery
Study: 10561307
Drug: Eniluracil treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eniluracil treatment
Study: 29569535
Drug: Vegetarian diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetarian diet combined with daily β-alanine (0.8-0.4 g/d) and creatine supplementation (1 g creatine monohydrate/d) (Veg+Suppl, n=15)
Study: 26078286
Drug: Alanyl-glutamine-supplemented parenteral
Normalized name: Alanyl glutamine
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alanyl-glutamine-supplemented parenteral nutrition (Gln-PN)
Study: 19417589
Drug: Gabadone (amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabadone (amino acid preparation)
Study: 17630491
Drug: Subcutaneous suturing
Normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous suturing of the subcutaneous fat tissue
Study: 17630491
Drug: No subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No subcutaneous suturing of the subcutaneous fat tissue
Study: 19116707
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (types 6, 11, 16, 18)
Study: 14999536
Drug: N-acetylcysteine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (50 mg kg(‐1) intravenously for 3 days)
Study: 10660922
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus acupressure training and treatment
Study: 9120912
Drug: Intravesical bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical bacillus Calmette-Guerin (BCG) therapy with isoniazid (300 mg daily)
Study: 9120912
Drug: Intravesical bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical bacillus Calmette-Guerin (BCG) therapy without isoniazid
Study: 8251274
Drug: Bupivacaine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 12.5 mg with adrenaline 25 micrograms and sufentanil 10 micrograms (Group A)
Study: 8251274
Drug: Bupivacaine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 12.5 mg with adrenaline 25 micrograms and clonidine 30 micrograms (Group B)
Study: 2418328
Drug: Doxorubicin chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin chemotherapy (60 mg/m2, i.v., given every 3 weeks, up to a maximum dose of 550 mg/m2)
Study: 11837735
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg intravenous erythromycin
Study: 31921879
Drug: 42 g
Normalized name: PETROLATUM 42 g in 100 g TOPICAL OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42 g pistachios
Study: 31921879
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g whole-wheat bread (WWB)
Study: 26474232
Drug: Pilates +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates + physical therapy (PPT)
Study: 28327054
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) only
Study: 24913169
Drug: Single-dose primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose primaquine treatment
Study: 17975496
Drug: Temsirolimus 25
Normalized name: temsirolimus 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus 25 mg
Study: 18441625
Drug: Multi sensory
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi sensory behavior therapy (MSBT) with standard psychiatric inpatient care
Study: 12168731
Drug: Daily leuprolide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily leuprolide acetate (Group 2)
Study: 2230623
Drug: Andrographis paniculata
Normalized name: Andrographis paniculata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrographis paniculata (AP) - single oral dose of 1, 2, 3, and 6 g
Study: 2230623
Drug: Andrographis paniculata
Normalized name: Andrographis paniculata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrographis paniculata (AP) - daily doses of 0.12-24 g per kg body weight for six months
Study: 2230623
Drug: Andrographis paniculata
Normalized name: Andrographis paniculata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrographis paniculata (AP) - direct assay of anti-bacterial activity in water solution (25,000 mg per litre)
Study: 31662863
Drug: Lanreotide (LAN)
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanreotide (LAN) 90 mg
Study: 27191767
Drug: Advanced formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced formulation of megestrol acetate containing nanocrystals (test formulation)
Study: 27191767
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation of megestrol acetate (reference formulation)
Study: 22282264
Drug: Both test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both test and reference formulations
Study: 24877242
Drug: 22-G SF-EUS-FNA
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 22-G SF-EUS-FNA
Study: 24877242
Drug: 25-G SF-EUS-FNA
Normalized name: SF-RI 1
DrugBank: Calfactant (DB06415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25-G SF-EUS-FNA
Study: 10802000
Drug: sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual nitroglycerin (300 microg)
Study: 10802000
Drug: low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose intravenous isoproterenol (mean infusion rate 1.3 +/- 0.5 microg/min)
Study: 10802000
Drug: sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual nitroglycerin test
Study: 10802000
Drug: low-dose isoproterenol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose isoproterenol test
Study: 8895233
Drug: Ketamine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (bolus at 0.1 mg/kg/5 min followed by an infusion of 7 micrograms/kg/min)
Study: 6309710
Drug: Neutron irradiation
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutron irradiation twice weekly
Study: 6309710
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (surgery, photon irradiation, or combined surgery and photon irradiation)
Study: 26792218
Drug: Concurrent twice‐daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent twice‐daily RT (45 Gy in 30 twice‐daily fractions over 3 weeks)
Study: 26792218
Drug: Concurrent once‐daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent once‐daily RT (66 Gy in 33 once‐daily fractions over 6.5 weeks)
Study: 3041354
Drug: Sandoglobulin (immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandoglobulin (immunoglobulin prepared for intravenous administration)
Study: 3041354
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with Sandoglobulin
Study: 3041354
Drug: Parenteral albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral albumin
Study: 28914720
Drug: Thoracic corrective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic corrective exercise program (1 hour/session, twice per week for 8 weeks, total of 16 sessions)